Claris Lifesciences has rallied 7% at Rs 222, also its 52-week high, after Barclays Capital Mauritius bought about 1% or 401,100 shares at Rs 162 per share through open market transaction.
Aditya Sushilkumar Handa, the promoter of the company, has sold 595,771 shares of Claris Lifesciences at Rs 162.09 on August 16, the BSE data shows.
On August 10, Barclays Capital Mauritius acquired 750,000 shares at price of Rs 162 per share from Aditya Sushilkumar Handa through bulk deal on BSE.
Meanwhile, generic sterile injectables maker has received the FDA's nod for plants in New Jersey and India.
“In a closeout letter filed this week, the FDA says the Indian company has made the needed improvements in the plants where contamination problems led to the agency's warning and the ban on products from the plant in Ahmedabad, India,” Claris said in a filing.
The stock has outperformed the market by surging 37% in past three-trading sessions as compared to less than 1% rise in benchmark Sensex.
As many as 544,000 shares have already changed hands on the counter so far, against an average 375,000 shares that were traded daily in past two weeks on the BSE.
